Teresa Gonzalez, APRN
Family · Paragould, ARNPI 1639481450
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 738 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 738 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$2K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$965
- Pfizer$722
- GSK$709
- plus $4K from 31 others
What the payments were for
- Food & beverage$11,61699%
- Education$1651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$819
- BREZTRI$694
- AIRSUPRA$396
- NURTEC ODT$224
- AREXVY$122
How this compares
$11,781 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 133 | $144,223 |
| MounjaroTirzepatide | 62 | $62,259 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $34,404 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $31,265 |
| JanuviaSitagliptin Phosphate | 31 | $30,388 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $29,206 |
| EliquisApixaban | 56 | $28,080 |
| FarxigaDapagliflozin Propanediol | 25 | $23,194 |
| Emgality PenGalcanezumab-Gnlm | 20 | $19,215 |
| MyrbetriqMirabegron | 22 | $16,200 |
| BrilintaTicagrelor | 30 | $16,039 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $16,005 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $11,481 |
| BelsomraSuvorexant | 26 | $10,522 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $7,618 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,552 | $144,223133 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Brilinta | $2,395 | $70,49788 claims |
| Lilly USA, LLCMounjaro | $636 | $62,25962 claims |
| MerckJanuvia, Belsomra | $123 | $40,91057 claims |
| PfizerEliquis | $722 | $28,08056 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $709 | $19,10026 claims |
| Astellas Pharma US IncMyrbetriq | $426 | $16,20022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.
Other family in Paragould
- Cecil MasseyParagould$13K
- Latoya CowardParagould$11K
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.